Linked Life Data

19272758

Source:http://linkedlifedata.com/resource/pubmed/id/19272758

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2009-4-28
pubmed:abstractText
Several studies and meta-analyses have implicated a polymorphism in the promoter region of the serotonin transporter (5-HTT) gene, 5-HTTLPR in treatment outcomes of selective serotonin re-uptake inhibitors in patients with major depression. In this study we investigated the impact of 5-HTTLPR and a functional SNP rs25531 on the treatment outcomes to escitalopram in depressive patients. The study sample consisted of 135 outpatients with major depressive disorder (mean age 31.1+/-11.6 years, 68% females) treated with escitalopram 10-20 mg/day for 12 weeks. There were no significant associations between 5-HTT promoter region polymorphisms and response rate or mean change of depressive symptoms during escitalopram treatment. However we showed that patients carrying S allele of 5-HTTLPR may have increased risk for some side effects, including headache, induced by escitalopram medication.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1873-7862
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
451-6
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression.
pubmed:affiliation
Research Department of Mental Health, North Estonia Medical Centre Foundation, Psychiatry Clinic, Tallinn, Estonia. Eduard.Maron@kliinikum.ee
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't